1 week ago

What's Going On With Tempus AI Stock Today?

Tempus AI (NASDAQ:TEM) rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors.

The next-generation model analyzes gene expression to help identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering what the company says is a more dynamic assessment of tumor biology than traditional genomic methods. In a real-world validation study, HRD-RNA–positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens saw a significant reduction in mortality risk compared with those receiving non-platinum therapies.

Tempus plans to make the test clinically available later this year. Chief Development Officer Halla Nimeiri said the algorithm provides physicians with a more functional view of HRD status by examining the transcriptome rather than the genome alone.

The announcement follows Tempus' recent non-exclusive distribution agreement with Median Technologies to expand AI-driven cancer diagnostics through the eyonis platform. Broader tech stocks also edged higher in the prior session, providing a supportive backdrop for the move.